Baker Bros. Advisors LP Summit Therapeutics Inc. Transaction History
Baker Bros. Advisors LP
- $8.39 Billion
- Q1 2025
A detailed history of Baker Bros. Advisors LP transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 24,424,865 shares of SMMT stock, worth $733 Million. This represents 5.62% of its overall portfolio holdings.
Number of Shares
24,424,865
Previous 24,424,865
-0.0%
Holding current value
$733 Million
Previous $436 Million
8.07%
% of portfolio
5.62%
Previous 4.83%
Shares
5 transactions
Others Institutions Holding SMMT
# of Institutions
246Shares Held
87.4MCall Options Held
1.77MPut Options Held
2.48M-
Vanguard Group Inc Valley Forge, PA11.6MShares$349 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$237 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$197 Million0.02% of portfolio
-
State Street Corp Boston, MA4.85MShares$146 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.28MShares$98.6 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $6.04B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...